Inari Medical, Inc.

Equities

NARI

US45332Y1091

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
47.98 USD +1.22% Intraday chart for Inari Medical, Inc. +6.10% -26.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Financial Stocks Gain Late Afternoon MT
Sector Update: Financial Stocks Rise Tuesday Afternoon MT
AppFolio to Join S&P MidCap 400, Inari Medical to Join S&P SmallCap 600; AppFolio Shares Rise MT
Sector Update: Tech Stocks Mixed Premarket Tuesday MT
Sector Update: Tech MT
AppFolio to Join S&P MidCap 400, Inari Medical to Join S&P SmallCap 600 MT
Truist Securities Cuts Inari Medical's Price Target to $52 From $61, Reiterates Hold Rating MT
Inari Medical Insider Sold Shares Worth $251,461, According to a Recent SEC Filing MT
Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry CI
Top Premarket Decliners MT
Piper Sandler Downgrades Inari Medical to Neutral From Overweight, Cuts Price Target to $55 From $85 MT
Morgan Stanley Lowers Price Target on Inari Medical to $75 From $83, Keeps Overweight Rating MT
Inari Medical Q4 Loss Narrows as Sales Increase -- Shares Decline Premarket MT
Transcript : Inari Medical, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (NARI) INARI MEDICAL Reports Q4 Revenue $132.1M, vs. Street Est of $132.1M MT
Inari Medical, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Inari Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inari Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Inari Medical, Inc. Announces Resignation of Kirk Nielsen from the Board Effective April 24, 2024 CI
Needham Initiates Inari Medical With Buy Rating, $72 PT; Notes 'Attractive' Valuation, Expects 'Rapid' Improvement in Margin, Earnings in 2025, Beyond MT
Transcript : Inari Medical, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
Inari Medical Reports Higher Q4, 2023 Preliminary Revenue; Provides 2024 Revenue Outlook MT
Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024 CI
Truist Securities Adjusts Price Target on Inari Medical to $70 From $65, Maintains Hold Rating MT
Inari Medical Insider Sold Shares Worth $1,627,073, According to a Recent SEC Filing MT
Chart Inari Medical, Inc.
More charts
Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of thrombus from the peripheral vasculature. Its ProTrieve sheath is used for the removal of thrombus from the peripheral vasculature through aspiration. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss. It also offers LimFlow System for Transcatheter Arterialization of the Deep Veins (TADV).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
47.98 USD
Average target price
73.7 USD
Spread / Average Target
+53.61%
Consensus